Noxopharm (ASX:NOX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Noxopharm (ASX:NOX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Pre-IND meeting request with US FDA
Noxopharm requests pre-IND meeting with US FDA for SOF-SKN autoimmune drug
Sofr platform versatility shown via childbirth MRFF grant
Fast-tracking of cancer program via novel animal model
SOF-SKN manufacturing begins to ensure clinical trial readi
Noxopharm begins SOF-SKN manufacturing ahead of clinical trial for autoimmune skin disease
Change of Director's Interest Notice
New data confirms cancer-fighting potential
Noxopharm's Sofra platform shows strong TLR8 immune activation, advancing cancer immunotherapy
Noxopharms Sofra assets to be presented at global conference
Noxopharm’s Sofra platform to feature at global influenza conference showcasing mRNA vaccine delivery potential
Proposed issue of securities - NOX
Noxopharm progresses US regulatory strategy
Noxopharm advances US FDA regulatory strategy for SOF-SKN with Novotech engagement
New data shows SOF-SKN active ingredient efficacy
Noxopharm's SOF-16 shows potent anti-inflammatory effects in lupus and rheumatoid arthritis patient samples
New Company Secretary appointed
Innovative collaboration further expands Sofra platform
Noxopharm and InhaTarget report strong lung inflammation reduction using Sofra™ inhalation delivery
March 2026 Quarterly Activities Report and Appendix 4C
Noxopharm signs MoU with Tezcat, publishes key Sofra research, appoints new CEO, reports positive trial and cash flow
Positive SOF-SKN dosing data shows prolonged skin retention
Noxopharm reports promising SOF-SKN dosing data showing prolonged skin retention and minimal systemic absorption
Noxopharm appoints Dr Olivier Laczka as new CEO
Noxopharm appoints Dr Olivier Laczka as new CEO to lead growth via Sofra technology
Change of & Final Directors Interest Notice (App 3Y & 3Z)-GM
Resignation of Chief Executive Officer
Noxopharm CEO Dr Gisela Mautner Resigns, Successor to be Announced Soon